By Associate Professor Deborah Cromer

Journal articles

Hastak P; Cromer D; Malycha J; Andersen CR; Raith E; Davenport MP; Plummer M; Sasson SC, 2024, 'Defining the correlates of lymphopenia and independent predictors of poor clinical outcome in adults hospitalized with COVID-19 in Australia', Scientific Reports, 14, http://dx.doi.org/10.1038/s41598-024-61729-5

Cromer D; Reynaldi A; Mitchell A; Schlub TE; Juno JA; Wheatley AK; Kent SJ; Khoury DS; Davenport MP, 2024, 'Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-52194-9

Revoltar M; van der Linde R; Cromer D; Gatt PN; Smith S; Fernandez MA; Vaughan L; Blyth E; Curnow J; Tegg E; Brown DA; Sasson SC, 2024, 'Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia', Pathology, 56, pp. 882 - 888, http://dx.doi.org/10.1016/j.pathol.2024.04.009

Elias KM; Khan SR; Stadler E; Schlub TE; Cromer D; Polizzotto MN; Kent SJ; Turner T; Davenport MP; Khoury DS, 2024, 'Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis', The Lancet Microbe, 5, pp. e459 - e467, http://dx.doi.org/10.1016/S2666-5247(23)00398-1

Stadler E; Cromer D; Ogunlade S; Ongoiba A; Doumbo S; Kayentao K; Traore B; Crompton PD; Portugal S; Davenport MP; Khoury DS, 2023, 'Evidence for exposure dependent carriage of malaria parasites across the dry season: modelling analysis of longitudinal data', Malaria Journal, 22, http://dx.doi.org/10.1186/s12936-023-04461-1

Stadler E; Burgess MT; Schlub TE; Khan SR; Chai KL; McQuilten ZK; Wood EM; Polizzotto MN; Kent SJ; Cromer D; Davenport MP; Khoury DS, 2023, 'Monoclonal antibody levels and protection from COVID-19', Nature Communications, 14, pp. 4545, http://dx.doi.org/10.1038/s41467-023-40204-1

Cromer D; Steain M; Reynaldi A; Schlub TE; Khan SR; Sasson SC; Kent SJ; Khoury DS; Davenport MP, 2023, 'Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis', Nature Communications, 14, pp. 1633, http://dx.doi.org/10.1038/s41467-023-37176-7

Stadler E; Chai KL; Schlub TE; Cromer D; Khan SR; Polizzotto MN; Kent SJ; Beecher C; White H; Turner T; Skoetz N; Estcourt L; McQuilten ZK; Wood EM; Khoury DS; Davenport MP, 2023, 'Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis', The Lancet Microbe, 4, pp. e883 - e892, http://dx.doi.org/10.1016/S2666-5247(23)00194-5

Docken SS; McCormick K; Pampena MB; Samer S; Lindemuth E; Pinkevych M; Viox EG; Wu Y; Schlub TE; Cromer D; Keele BF; Paiardini M; Betts MR; Bar KJ; Davenport MP, 2023, 'Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency', PLoS Pathogens, 19, http://dx.doi.org/10.1371/journal.ppat.1011755

Zachreson C; Tobin R; Szanyi J; Walker C; Cromer D; Shearer FM; Conway E; Ryan G; Cheng A; McCaw JM; Geard N, 2023, 'Individual variation in vaccine immune response can produce bimodal distributions of protection', Vaccine, 41, pp. 6630 - 6636, http://dx.doi.org/10.1016/j.vaccine.2023.09.025

Lee WS; Tan HX; Reynaldi A; Esterbauer R; Koutsakos M; Nguyen J; Amarasena T; Kent HE; Aggarwal A; Turville SG; Taiaroa G; Kinsella P; Liew KC; Tran T; Williamson DA; Cromer D; Davenport MP; Kent SJ; Juno JA; Khoury DS; Wheatley AK, 2023, 'Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adg5301

Khoury DS; Docken SS; Subbarao K; Kent SJ; Davenport MP; Cromer D, 2023, 'Predicting the efficacy of variant-modified COVID-19 vaccine boosters', Nature Medicine, 29, pp. 574 - 578, http://dx.doi.org/10.1038/s41591-023-02228-4

Khoury DS; Schlub TE; Cromer D; Steain M; Fong Y; Gilbert PB; Subbarao K; Triccas JA; Kent SJ; Davenport MP, 2023, 'Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection', Emerging Infectious Diseases, 29, pp. 381 - 388, http://dx.doi.org/10.3201/eid2902.221422

Selva KJ; Ramanathan P; Haycroft ER; Reynaldi A; Cromer D; Tan CW; Wang LF; Wines BD; Hogarth PM; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW, 2023, 'Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections', JCI Insight, 8, http://dx.doi.org/10.1172/jci.insight.172470

Stadler E; Cromer D; Mehra S; Adekunle AI; Flegg JA; Anstey NM; Watson JA; Chu CS; Mueller I; Robinson LJ; Schlub TE; Davenport MP; Khoury DS, 2022, 'Population heterogeneity in Plasmodium vivax relapse risk', PLoS Neglected Tropical Diseases, 16, http://dx.doi.org/10.1371/journal.pntd.0010990

SheelaNair A; Romanczuk AS; Aogo RA; Haldar RN; Lansink LIM; Cromer D; Salinas YG; Guy RK; McCarthy JS; Davenport MP; Haque A; Khoury DS, 2022, 'Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice', Malaria Journal, 21, http://dx.doi.org/10.1186/s12936-022-04075-z

Koutsakos M; Lee WS; Reynaldi A; Tan HX; Gare G; Kinsella P; Liew KC; Taiaroa G; Williamson DA; Kent HE; Stadler E; Cromer D; Khoury DS; Wheatley AK; Juno JA; Davenport MP; Kent SJ, 2022, 'The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants', Immunity, 55, pp. 1316 - 1326.e4, http://dx.doi.org/10.1016/j.immuni.2022.05.018

Cromer D; Reynaldi A; Steain M; Triccas JA; Davenport MP; Khoury DS, 2022, 'Relating in Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial', Clinical Infectious Diseases, 75, pp. E878 - E879, http://dx.doi.org/10.1093/cid/ciac075

Kent SJ; Khoury DS; Reynaldi A; Juno JA; Wheatley AK; Stadler E; John Wherry E; Triccas J; Sasson SC; Cromer D; Davenport MP, 2022, 'Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?', Nature Reviews Immunology, 22, pp. 387 - 397, http://dx.doi.org/10.1038/s41577-022-00716-1

Aggarwal A; Stella AO; Walker G; Akerman A; Esneau C; Milogiannakis V; Burnett DL; McAllery S; Silva MR; Lu Y; Foster CSP; Brilot F; Pillay A; Van Hal S; Mathivanan V; Fichter C; Kindinger A; Hoppe AC; Munier ML; Amatayakul-Chantler S; Roth N; Coppola G; Symonds GP; Schofield P; Jackson J; Lenthall H; Henry JY; Mazigi O; Jäck HM; Davenport MP; Darley DR; Matthews GV; Khoury DS; Cromer D; Goodnow CC; Christ D; Robosa R; Starck DJ; Bartlett NW; Rawlinson WD; Kelleher AD; Turville SG, 2022, 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', Nature Microbiology, 7, pp. 896 - 908, http://dx.doi.org/10.1038/s41564-022-01135-7

Cele S; Jackson L; Khoury DS; Khan K; Moyo-Gwete T; Tegally H; San JE; Cromer D; Scheepers C; Amoako DG; Karim F; Bernstein M; Lustig G; Archary D; Smith M; Ganga Y; Jule Z; Reedoy K; Hwa SH; Giandhari J; Blackburn JM; Gosnell BI; Abdool Karim SS; Hanekom W; Davies MA; Hsiao M; Martin D; Mlisana K; Wibmer CK; Williamson C; York D; Harrichandparsad R; Herbst K; Jeena P; Khoza T; Kløverpris H; Leslie A; Madansein R; Magula N; Manickchund N; Marakalala M; Mazibuko M; Moshabela M; Mthabela N; Naidoo K; Ndhlovu Z; Ndung’u T; Ngcobo N; Nyamande K; Patel V; Smit T; Steyn A; Wong E; von Gottberg A; Bhiman JN; Lessells RJ; Moosa MYS; Davenport MP; de Oliveira T; Moore PL; Sigal A, 2022, 'Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization', Nature, 602, pp. 654 - 656, http://dx.doi.org/10.1038/s41586-021-04387-1

Cromer D; Steain M; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Kent SJ; Triccas JA; Khoury DS; Davenport MP, 2022, 'Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis', The Lancet Microbe, 3, pp. e52 - e61, http://dx.doi.org/10.1016/S2666-5247(21)00267-6

Aggarwal A; Stella A; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Lenthall H; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fitcher C; Hoppe AC; Munier ML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2022, 'SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern', , http://dx.doi.org/10.21203/rs.3.rs-1207364/v1

Wheatley AK; Juno JA; Wang JJ; Selva KJ; Reynaldi A; Tan HX; Lee WS; Wragg KM; Kelly HG; Esterbauer R; Davis SK; Kent HE; Mordant FL; Schlub TE; Gordon DL; Khoury DS; Subbarao K; Cromer D; Gordon TP; Chung AW; Davenport MP; Kent SJ, 2021, 'Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-21444-5

Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH, 2021, 'Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain', Cell Reports, 37, http://dx.doi.org/10.1016/j.celrep.2021.109822

Khoury DS; Cromer D; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Subbarao K; Kent SJ; Triccas JA; Davenport MP, 2021, 'Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection', Nature Medicine, 27, pp. 1205 - 1211, http://dx.doi.org/10.1038/s41591-021-01377-8

Lee WS; Selva KJ; Davis SK; Wines BD; Reynaldi A; Esterbauer R; Kelly HG; Haycroft ER; Tan HX; Juno JA; Wheatley AK; Hogarth PM; Cromer D; Davenport MP; Chung AW; Kent SJ, 2021, 'Decay of Fc-dependent antibody functions after mild to moderate COVID-19', Cell Reports Medicine, 2, http://dx.doi.org/10.1016/j.xcrm.2021.100296

Cromer D; Juno JA; Khoury D; Reynaldi A; Wheatley AK; Kent SJ; Davenport MP, 2021, 'Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection', Nature Reviews Immunology, 21, pp. 395 - 404, http://dx.doi.org/10.1038/s41577-021-00550-x

Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH, 2021, 'Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice', Proceedings of the National Academy of Sciences of the United States of America, 118, http://dx.doi.org/10.1073/pnas.2101918118

Cromer D; Reynaldi A; Steain M; Triccas J; Davenport M; Khoury D, 2021, 'Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial', , http://dx.doi.org/10.1101/2021.06.29.21259504

Cromer D; Steain M; Reynaldi A; Schlub T; Wheatley A; Juno J; Kent S; Triccas J; Khoury D; Davenport M, 2021, 'SARS-CoV-2 variants: levels of neutralisation required for protective immunity', , http://dx.doi.org/10.1101/2021.08.11.21261876

Khoury D; Cromer D; Reynaldi A; Schlub T; Wheatley A; Juno J; Subbarao K; Kent S; Triccas J; Davenport M, 2021, 'What level of neutralising antibody protects from COVID-19?', , http://dx.doi.org/10.1101/2021.03.09.21252641

Khoury DS; Wheatley AK; Ramuta MD; Reynaldi A; Cromer D; Subbarao K; O’Connor DH; Kent SJ; Davenport MP, 2020, 'Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models', Nature Reviews Immunology, 20, pp. 727 - 738, http://dx.doi.org/10.1038/s41577-020-00471-1

Alahmadi A; Belet S; Black A; Cromer D; Flegg JA; House T; Jayasundara P; Keith JM; McCaw JM; Moss R; Ross JV; Shearer FM; Tun STT; Walker CR; White L; Whyte JM; Yan AWC; Zarebski AE, 2020, 'Influencing public health policy with data-informed mathematical models of infectious diseases: Recent developments and new challenges', Epidemics, 32, http://dx.doi.org/10.1016/j.epidem.2020.100393

Wu Y; Pinkevych M; Xu Z; Keele BF; Davenport MP; Cromer D, 2020, 'Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption', Proceedings of the Royal Society B: Biological Sciences, 287, http://dx.doi.org/10.1098/rspb.2020.0354

Price DJ; Shearer FM; Meehan MT; McBryde E; Moss R; Golding N; Conway EJ; Dawson P; Cromer D; Wood J; Abbott S; McVernon J; McCaw JM, 2020, 'Early analysis of the australian covid-19 epidemic', eLife, 9, pp. 1 - 14, http://dx.doi.org/10.7554/ELIFE.58785

Khoury DS; Zaloumis SG; Grigg MJ; Haque A; Davenport MP; Cromer D; Rebelo M; Cao P; McCaw JM; Simpson JA; Flegg JA; Wilson DW; Anstey NM; McCarthy JS, 2020, 'Malaria Parasite Clearance: What Are We Really Measuring?', Trends in Parasitology, 36, pp. 413 - 426, http://dx.doi.org/10.1016/j.pt.2020.02.005

Pinkevych M; Fennessey CM; Cromer D; Reid C; Trubey CM; Lifson JD; Keele BF; Davenport MP, 2019, 'Predictors of SIV recrudescence following antiretroviral treatment interruption', eLife, 8, pp. e49022, http://dx.doi.org/10.7554/eLife.49022

Khoury DS; Cromer D; Möhrle JJ; McCarthy JS; Davenport MP, 2019, 'Corrigendum: Defining the effectiveness of antimalarial chemotherapy: Investigation of the lag in parasite clearance following drug administration (Journal of Infectious Diseases (2016) 214 (753-761) DOI: 10.1093/infdis/jiw234)', Journal of Infectious Diseases, 219, pp. 1852 - 1853, http://dx.doi.org/10.1093/infdis/jiy729

Akter J; Khoury DS; Aogo R; Lansink LIM; SheelaNair A; Thomas BS; Laohamonthonkul P; Pernold CPS; Dixon MWA; Soon MSF; Fogg LG; Engel JA; Elliott T; Sebina I; James KR; Cromer D; Davenport MP; Haque A, 2019, 'Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells', PLoS Pathogens, 15, pp. e1007599, http://dx.doi.org/10.1371/journal.ppat.1007599

Davenport MP; Khoury DS; Cromer D; Lewin SR; Kelleher AD; Kent SJ, 2019, 'Functional cure of HIV: the scale of the challenge', Nature Reviews Immunology, 19, pp. 45 - 54, http://dx.doi.org/10.1038/s41577-018-0085-4

Zaloumis SG; Cao P; Dini S; Davenport MP; Cromer D; Khoury DS; Fowkes FJI; McCaw JM; Simpson JA, 2018, 'In silico investigation of the decline in clinical efficacy of artemisinin combination therapies due to increasing artemisinin and partner drug resistance', Antimicrobial Agents and Chemotherapy, 62, pp. 10.1128/aac.01292 - 10.1128/aac.01218, http://dx.doi.org/10.1128/AAC.01292-18

Aogo RA; Khoury DS; Cromer D; Elliott T; Akter J; Fogg LG; Nair AS; Liligeto UN; Soon MSF; Thomas BS; Pernold CPS; Romanczuk AS; Laohamonthonkul P; Haque A; Davenport MP, 2018, 'Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice', International Journal for Parasitology, 48, pp. 903 - 913, http://dx.doi.org/10.1016/j.ijpara.2018.05.010

Khoury DS; Aogo R; Randriafanomezantsoa-Radohery G; McCaw JM; Simpson JA; McCarthy JS; Haque A; Cromer D; Davenport MP, 2018, 'Within-host modeling of blood-stage malaria', Immunological Reviews, 285, pp. 168 - 193, http://dx.doi.org/10.1111/imr.12697

Parsons MS; Cromer D; Davenport MP; Kent SJ, 2018, 'HIV Reactivation after Partial Protection by Neutralizing Antibodies', Trends in Immunology, 39, pp. 359 - 366, http://dx.doi.org/10.1016/j.it.2017.12.006

Pinkevych M; Fennessey CM; Cromer D; Tolstrup M; Søgaard OS; Rasmussen TA; Keele BF; Davenport MP, 2018, 'Estimating initial viral levels during simian immunodeficiency virus/human immunodeficiency virus reactivation from latency', Journal of Virology, 92, http://dx.doi.org/10.1128/JVI.01667-17

Khoury DS; Cromer D; Elliott T; Soon MSF; Thomas BS; James KR; Best SE; Aogo RA; Engel JA; Gartlan KH; Akter J; Sebina I; Haque A; Davenport MP, 2017, 'Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo', International Journal for Parasitology, 47, pp. 913 - 922, http://dx.doi.org/10.1016/j.ijpara.2017.05.009

Cromer D; Pinkevych M; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP, 2017, 'Modeling of antilatency treatment in HIV: What is the optimal duration of antiretroviral therapy-free HIV remission?', Journal of Virology, 91, pp. 10.1128/jvi.01395 - 10.1128/jvi.01317, http://dx.doi.org/10.1128/JVI.01395-17

Cao P; Klonis N; Zaloumis S; Khoury DS; Cromer D; Davenport MP; Tilley L; Simpson JA; McCaw JM, 2017, 'A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection', Journal of Theoretical Biology, 430, pp. 117 - 127, http://dx.doi.org/10.1016/j.jtbi.2017.07.017

Cromer D; van Hoek AJ; Newall AT; Pollard AJ; Jit M, 2017, 'Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England', The Lancet Public Health, 2, pp. e367 - e374, http://dx.doi.org/10.1016/S2468-2667(17)30103-2

Back to profile page